McKesson Corporation: Q1 2007 Financial Summary (Form 10-Q)
Business Context and Reporting Period
This report covers the quarter ended June 30, 2006 (Fiscal Q1 2007). McKesson Corporation operates as a leading healthcare services company with three primary segments: Pharmaceutical Solutions, Medical-Surgical Solutions, and Provider Technologies. The company is a large accelerated filer incorporated in Delaware.
Key Financial Metrics
| Metric | Q1 2007 | Q1 2006 |
|---|---|---|
| Revenues | $23,616 million | $20,968 million |
| Gross Profit | $1,023 million | $925 million |
| Operating Income | $272 million | $261 million |
| Net Income | $184 million | $171 million |
| Diluted EPS | $0.60 | $0.55 |
| Operating Cash Flow | $295 million | $638 million |
| Cash and Equivalents | $2,000 million | $2,142 million |
| Long-Term Debt | $962 million | $965 million |
| Working Capital | $3,287 million | $3,404 million |
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 13% year-over-year, driven primarily by the Pharmaceutical Solutions segment (95% of total revenue). Growth was fueled by the acquisition of D&K Healthcare Resources and expanded customer agreements.
- Margin Compression: Gross profit margin decreased 8 basis points to 4.33%. This decline was largely due to the absence of a $51 million anti-trust settlement credit recorded in the prior year. Excluding this item, margins improved.
- Operating Expenses: Total operating expenses rose 13% to $751 million. This increase reflects business acquisitions, volume growth, and the adoption of SFAS No. 123(R) for share-based compensation. Notably, the $52 million Securities Litigation charge recorded in Q1 2006 was absent in the current quarter.
- Cash Flow: Operating cash flow decreased significantly to $295 million from $638 million, primarily due to a $446 million increase in inventory levels to support revenue growth, offset by improvements in receivables and payables.
- Share Repurchases: The company repurchased 6 million shares for $283 million during the quarter.
Guidance, Outlook, and Risks
- Accounting Changes: The company adopted SFAS No. 123(R) on April 1, 2006. Management expects share-based compensation charges in fiscal 2007 to approximate $0.08 to $0.10 per diluted share, an increase of $0.05 to $0.07 per share compared to 2006.
- Strategic Transactions:
- Acquisitions: Acquired Sterling Medical Services, HealthCom Partners, and RelayHealth for $87 million in Q1 2007.
- Investment: Contributed $81 million in assets to Parata Systems, LLC for a minority interest, resulting in a $15 million charge to cost of sales.
- Divestiture: Signed an agreement to sell the Acute Care business of the Medical-Surgical segment to Owens & Minor for $170 million; expected to close in Q3 2007.
- Litigation: A $1,008 million accrual remains for Securities Litigation related to the 1999 HBOC accounting issues. While management believes the reserve is adequate, ultimate costs could vary. An ERISA settlement of approximately $19 million is pending final approval.
- Capital Resources: The company maintains a $1.3 billion revolving credit facility and a $700 million accounts receivable sales facility. The debt-to-capital ratio stands at 14.3%, well below the 56.5% covenant limit.
Investor Verification Checklist
- Verify the impact of the $51 million anti-trust settlement exclusion on year-over-year margin comparisons.
- Monitor the execution of the $170 million sale of the Acute Care business and associated restructuring charges.
- Assess the adequacy of the $1,008 million Securities Litigation reserve given ongoing legal proceedings.
- Review the trajectory of inventory levels, which increased by $454 million quarter-over-quarter, and its effect on working capital.
- Confirm the actual share-based compensation expense in future quarters against the $0.08–$0.10 per share guidance.